Evidence map›Paper›PMID 40895618›Full record

ArticleFrontiers in endocrinology2025

Global burden and risk factors of type 2 diabetes mellitus from 1990 to 2021, with forecasts to 2050.

Qian Huang, Yang Li, Minggang Yu, Zhizi Lv, Fengyi Lu, Ning Xu, Qingqing Zhang, Jiayun Shen, Jinfeng Zhu, Hua Jiang

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Antidiabetic Effects ofMarine drugs · 2026
    Article
  8. Review
  9. Article
  10. Review
  11. Physicochemical, Technofunctional and Antiglycaemic Properties ofInternational journal of food science · 2026
    Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qian HuangDepartment of General Practice, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Yang LiDepartment of General Practice, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Minggang YuDepartment of General Practice, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Zhizi LvDepartment of General Practice, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Fengyi LuDepartment of General Practice, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Ning XuDepartment of General Practice, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Qingqing ZhangDepartment of General Practice, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Jiayun ShenDepartment of General Practice, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.
Jinfeng ZhuHunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, China.
Hua JiangDepartment of General Practice, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Type 2 diabetes mellitus (T2DM) presents a substantial strain on global healthcare systems. This study seeks to offer robust scientific evidence for the effective prevention and management of T2DM globally through a comprehensive analysis of the disease's burden, trends, and risk factors from 1990 to 2021, as well as future trajectories from 2022 to 2050. Methods: Data for this study were sourced from the 2021 Global Burden of Disease (GBD) study. T2DM burden was assessed through incidence, prevalence, mortality, and disability-adjusted life years (DALYs), stratified by age, sex, sociodemographic index (SDI), 21 GBD regions, and 204 countries/territories. Trends from 1990 to 2021 were quantified by estimating annual percentage changes. Decomposition analysis identified the primary population-level drivers of T2DM burden changes. The population attributable fraction assessed the contribution of risk factors to the T2DM burden over the past 30 years, while the Bayesian age-period-cohort model was employed to predict the future burden driven by risk factors. Results: In 2021, T2DM affected 506.0 million individuals, with 23.9 million new cases, 1.6 million deaths, and 75.3 million DALYs. Between 1990 and 2021, both absolute and relative burdens of T2DM increased, particularly among males, older adults, and individuals under 40. Regions with higher SDI generally exhibited higher age-standardized incidence and prevalence rates, while those with lower SDI had elevated age-standardized mortality and DALY rates. Oceania stood out as an exception, with the highest relative burdens across all four indicators, most notably in the Marshall Islands and Fiji. The increases in incidence, DALYs, and prevalence were predominantly driven by population growth and epidemiological shifts, with aging contributing significantly to the rise in mortality. Elevated fasting plasma glucose, body mass index (BMI), and particulate pollution were major contributors to higher T2DM-related mortality and DALY rates. By 2050, high BMI, alcohol consumption, and sugary beverages are anticipated to increasingly influence the T2DM burden. Conclusion: Focused, preventive interventions targeting key risk factors in high-burden groups can effectively reduce the global T2DM burden.

Indexed as

Diabetes Mellitus, Type 2Global Burden of DiseaseAdultAgedCost of IllnessDisability-Adjusted Life YearsFemaleForecastingGlobal HealthHumansIncidenceMaleMiddle AgedPrevalenceQuality-Adjusted Life YearsRisk Factorsdecomposition analysisforecastglobal burdenrisk factorsociodemographic indextrend analysistype 2 diabetes mellitus

Identifiers

PMID40895618
PMCPMC12390814

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.